Alto Neuroscience (ANRO) Corporate presentation summary

Mission and strategic approach

• Aims to redefine psychiatry by developing personalized, neurobiology-driven medicines for mental health disorders.

• Focuses on precision medicine for CNS, using biomarkers to identify responsive patient populations and improve clinical outcomes.

• Addresses unmet needs in mental health, targeting depression, schizophrenia, and bipolar disorder with novel mechanisms.

• Utilizes a biomarker platform to segment patients and guide drug development, reducing trial-and-error in treatment.

• Leverages proprietary cognitive and EEG-based biomarkers for patient selection and monitoring.

Pipeline and clinical programs

• ALTO-207 (TRD): Combines D3/D2 agonist and 5-HT3 antagonist, showing robust antidepressant effects and improved tolerability; pivotal Phase 2b and Phase 3 trials planned for 2026–2027.

• ALTO-300 (MDD): Multi-modal antidepressant (agomelatine) with EEG biomarker-guided patient selection; Phase 2b ongoing, topline data expected mid-2026.

• ALTO-100 (Bipolar Depression): Enhances hippocampal neuroplasticity, with Phase 2b trial in biomarker-positive patients; topline data expected 2H 2026.

• ALTO-101 (CIAS): Novel PDE4 inhibitor for cognitive impairment in schizophrenia, showing pro-cognitive effects and ongoing POC study; data expected 1Q 2026.

• ALTO-203 (MDD): H3 inverse agonist with effects on multiple neurotransmitter systems, showing positive pharmacodynamic effects in early studies.

Clinical and commercial highlights

• Over 800 patients dosed across studies, with more than 25 million patient impact opportunity.

• Multiple mid- to late-stage data readouts expected in the next two years.

• Cash runway projected into 2028, with $184.2 million as of October 2025.

• Strong IP portfolio and commercial strategies to mitigate generic substitution risks.

• Recent analogs in psychiatry support the combination approach and novel mechanisms, indicating blockbuster potential for lead candidates.